What just happened this week in the stock market? The market spent most of the week digesting AI volatility, geopolitical headlines, and what may end up being one of the biggest financial events of the decade: the IPO of SpaceX ($SPCX). By Friday, the major indexes had recovered and finished higher, with the S&P 500 up 0.5%, the Dow up 0.7%, and the Nasdaq up 0.3% on the day. Small caps quietly outperformed again, with the Russell 2000 ($IWM) gaining 3.9% for the week. The biggest headline was undoubtedly SpaceX ($SPCX). The company raised roughly $75 billion in the largest IPO ever and finished its first day up about 19%, ending with a valuation above $2 trillion. The size of the offering was so large that analysts are already debating whether the old “Magnificent Seven” label still makes sense in a world where SpaceX ($SPCX), OpenAI and Anthropic are emerging as trillion-dollar AI-era companies. AI stocks were all over the place. Earlier in the week, semiconductors sold off sharply, with Nvidia ($NVDA), Tesla ($TSLA) and many AI-linked names getting hit. By the end of the week, investors had largely bought the dip and sentiment improved. Intel ($INTC) was one of the surprise winners, jumping around 11% after reports that AI chipmakers may increasingly use Intel’s manufacturing capacity. Micron ($MU) surged nearly 10%, AMD ($AMD) gained more than 5%, while Nvidia ($NVDA) recovered after a volatile week. Apple ($AAPL) had a rougher week. Investors were not particularly impressed by its latest AI announcements, and shares fell after WWDC. The market increasingly wants to see real AI products driving revenue rather than promises. Oracle ($ORCL) became one of the most closely watched companies after strong AI-related momentum and continued investor focus on cloud infrastructure spending. The AI arms race is now expected to drive almost $1 trillion of infrastructure spending across major hyperscalers over the next year. In biotech, several names made outsized moves. Tango Therapeutics ($TNGX) exploded higher after encouraging cancer data, reminding investors that clinical results still matter more than market narratives. Healthcare also continued to show relative strength while some investors rotated away from crowded AI trades. Outside technology, falling oil prices helped the broader market. Hopes of a U.S.-Iran agreement reduced fears of energy inflation, which gave investors confidence that interest rates may not need to rise as aggressively as feared. My biggest takeaway from the week: market leadership is broadening. For much of the last two years, it felt like everything revolved around Nvidia ($NVDA) and a handful of mega-cap tech names. This week showed money moving into small caps, healthcare, industrials and selected biotechs while AI remains the dominant long-term theme. That is usually a healthier market than one carried by only seven stocks. #Stocks #Investing #StockMarket #AI #SpaceX #WeeStocks

A biotech company is keeping recently deceased human brains active on a high-tech life-support system. The reasons? The company says they want to pave the way for an animal-free era of neurological drug testing. Spun out of Yale University research, biotechnology startup Bexorg is challenging traditional drug testing boundaries by placing donated human brains on an artificial life-support system called BrainEx. Shortly after a donor's death, the company connects the bodiless organ to pumps that circulate an oxygen-rich, nutrient-dense blood substitute to restore cellular and metabolic activity. To address the immediate ethical concerns surrounding consciousness, Bexorg keeps these brains under deep anesthesia using propofol, ensuring there is no organized neural firing or awareness. The organs remain active for just 24 hours—providing researchers with a critical window to test drugs for diseases like Alzheimer's and Parkinson's on actual human tissue—before being dissected for detailed analysis. This whole-organ technology is part of a broader, high-stakes shift toward replacing flawed animal models, which contribute to a staggering failure rate in central nervous system drug trials. Other forward-looking companies are pursuing alternative biological avenues; Tessara Therapeutics is growing thousands of miniature, human stem-cell-derived 'mini-brains,' while Cortical Labs has engineered a platform that embeds living neurons onto silicon chips. Even more radically, startups like R3 Bio are exploring genetically engineered, brainless human bodies to serve as whole-body medical models. Together, these groundbreaking platforms could significantly accelerate the development of life-saving therapeutics while moving medicine beyond the ethical and biological limitations of animal testing. source: Cross, R. (2025). Exclusive: Rebooting dead human brains, a biotech startup seeks to reinvent early drug testing work. Endpoints News.

Can precision oncology create extraordinary shareholder value? Explore Nuvalent ($NUVL), its targeted cancer therapy pipeline, competitive advantages, acquisition by GSK, and long-term investment outlook. thekatyalyst.org/nuvalent-in… #NUVL #Biotech

AI x Biotech has been on Fabian’s radar inside MHC for a while. Now the market is red, and healthcare/pharma is one of the few areas still holding green. This is why you want people like @_FabianHD watching the tape for you.

Biotech companies must base their future on scientific innovation. This requires deep understanding on biology, which today requires data and AI. Look at the correlation of timing between GDPR and emigration of European biotech...

They're automating research labs in everything from chemicals, advanced materials, biotech, and anything else you might think of. I don't know how fast the returns will be, but it is a bigger wave than implied here.

💥 Stocks Near 200-EMA 👀 📊 Often a key support/resistance zone where big moves can begin. 🔹 INDOCO 🔹 IDFC First Bank 🔹 AIIL 🔹 TBZ 🔹 Can Fin Homes 🔹 GAIL 🔹 Concord Biotech 🔹 Ramkrishna Forgings 🔹 Religare 🔹 V-Mart 🔹 Kotak Mahindra Bank 🔹 Page Industries 📌 Keep these stocks on your watchlist. #200EMA #StocksToWatch #TechnicalAnalysis #IDFCFirstBank #KotakBank #GAIL #StockMarketIndia #Trading

Legend Biotech reports 100% ORR in LB2501 trial.

quantum powered simulations for biotech sounds really promising

dropbox.com/scl/fi/yv9lzrs9l… why was a uk Government Minister having meeting with Big Pharma companies in 2015, and why were UK pharma and biotech trade associations there, and Government departments???

Pharma = spiritual leftism Mitochondria raped by Superoxide? Pharma: Intravenous Gkt2812471847714, Gene editing, Alien biotech, Recombinant synthetic human SOD. Cross fingers. Real Solution: A bit more Manganese for Manganese-Dependent SOD2.

What does it take to be considered "technical" in biotech, if the tech startup jargon were to be shoehorned in?

youtube.com/live/brjCi53W02M Today, Sunday, June 14, 2026, at 1 p.m. U.S. Pacific Time, watch a compilation stream of four presentations from the May 3, 2026, sessions at the University of California, Berkeley Conference on Aging and Longevity (BerkeleyCAL), hosted by Professor Steven A. Garan, Director of Bioinformatics at the Center for Research and Education on Aging. These presentations focus on the societal, economic, and advocacy aspects of the field of longevity and anti-aging and range from comprehensive overviews of the longevity sector to approaches for improving the health of the public and catalyzing scientific breakthroughs. Speakers in this stream include Scott Summit, Brian Wang (@nextbigfuture), Laurence Ion (@longevion), and Karl R. Pfleger (@KarlPfleger). This is the first of multiple streams that the U.S. Transhumanist Party is compiling in order to bring the proceedings of the BerkeleyCAL to a wider audience. Presentations include question-and-answer sessions, where I asked several in-depth questions and received thoughtful answers from the speakers. Members of the public will be able to post questions and comments in the live YouTube chat. Scott Summit of Ethereal Matter, Inc. – ethereal-space.org/– presents a robotic solution designed to combat the global health crisis caused by sedentary lifestyles by gamifying fitness through immersive VR experiences. His platform utilizes motion capture and advanced robotics to create personalized, engaging, and physically challenging environments that encourage users to exercise consistently. By leveraging the same technology that drives sedentary gaming addiction, this system aims to bridge the gap between entertainment and preventative health for all ages. The Salon stream also includes some brief footage that I captured of one of the VR worlds within Ethereal Matter’s MEK exercise machine. Brian Wang of NextBigFuture – nextbigfuture.com/– highlights the San Francisco Bay Area as a global powerhouse for both biotech and longevity research, noting its immense concentration of companies, funding, and expertise. He explains that the longevity sector is growing rapidly, with significant backing from billionaires funding major ventures. Finally, he emphasizes the potential public health and economic benefits of longevity technologies, suggesting they could mirror the transformative, large-scale impact of recent weight-loss treatments. Lawrence Ion discusses his mission to accelerate longevity research by building a semi-autonomous city, Viva City – viva.city/– designed to circumvent bureaucratic hurdles and overregulation in traditional medical science. He argues for a decentralized, "bottom-up" approach—leveraging communities like VitaDAO and experimental pop-up villages—to foster innovation and rapidly bring life-saving therapies to market. Through this initiative, Ion aims to establish a new legal and regulatory sandbox that empowers individuals with the freedom to pursue advanced longevity interventions more safely and efficiently than current systems allow. Dr. Karl R. Pfleger of AgingBiotech.info – agingbiotech.info/ – investor and author with a rigorously systematic approach, presents a comprehensive overview of the aging and longevity field, emphasizing the shift to treating aging as a manageable pathology through the Geroscience Hypothesis. He analyzes the current status of the sector, noting that while the pipeline of FDA-approved aging therapeutics is just beginning to emerge, there is a clear, data-backed trajectory of future growth. Finally, Pfleger distinguishes between two primary research strategies—broadly slowing aging through monotherapies and the divide-and-conquer rejuvenation approach. View the slides for Karl Pfleger’s presentation – “Motivation for, status of, path to eliminating aging”: docs.google.com/presentation… The BerkeleyCAL was hosted at the University of California, Berkeley, in Stanley Hall, and was organized by Dr. Michael Conboy, Dr. Steven A. Garan, Dr. Nuno R. B. Martins, and Dr. Anthony T. Iavarone, with significant assistance from Melissa King and Bernard Siegel of the Healthspan Action Coalition: healthspanaction.org/.

Rs. 10,000 Crore has been sanctioned for Biopharma Shakti! More than 11800 BioTech Startups have started their journey! #12YearsOfSwasthBharat @PMOIndia @HMOIndia @PIB_India @MIB_India @PIB_Guwahati

most people predict the future badly. because they chase trends. ai crypto robots space biotech but futurists don’t start with hype. they ask better questions: what is changing? what is stable? what is accelerating? what is constrained? what incentives are shaping behavior? think like a futurist — cecily sommers is about seeing the future as a system, not a headline. technology changes fast. human needs change slowly. institutions resist change. markets reward leverage. biology stays brutally consistent. the future is not guessed. it is mapped through forces. weak signals become patterns. patterns become trajectories. trajectories become strategy. most people react to change. futurists study the structure underneath it.

Country highlight: Nigeria will train 10,000 pharma/biotech professionals and expand regional manufacturing of vaccines, medicines, and diagnostics. #HealthWorks wrld.bg/LwaS50ZbiXA @Fmohnigeria @muhammadpate @FinMinNigeria

30k nukes, 40k tons of chemicals, biotech sites... suddenly no central government. The real question isn't why they got involved. It's what should happen to orphaned Soviet weapons.

Biotech mit Schutzschild: NurExone baut internationale Patentbasis für dlvr.it/TT27H9

Absolutely not. TCS senior analyst don't need those tokens. It's for biotech, military,etc